Innate Pharma is a French biotech partnered with AstraZeneca. The company pursued a public equity offering that was targeting $100 million by proposing to sell 10.7 million shares at $7.50 each. The planned IPO was priced down by 13%, and the transaction raised $69 million. The article provides no operational or product details beyond the AstraZeneca partnership. No investor syndicate or additional financing instruments are disclosed in the available text. Additional financial metrics, founding year, and location details beyond 'French' are not provided in the article excerpt.

Total raised

$69M

Funding rounds

1

Latest round

Equity

Latest activity

Oct 2019